Overview

Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well bortezomib works in treating patients with newly diagnosed multiple myeloma. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Bortezomib